Ratings
0
Nobody has rated this yet. Be the first!
Works
12
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer
Para-aortic lymph node surgical staging in locally-advanced cervical cancer: comparison between robotic versus conventional laparoscopy
PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy
Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients
TRP channel expression correlates with the epithelial-mesenchymal transition and high-risk endometrial carcinoma
ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer
Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study
